Immunophenotypic Differences in MGUS and Plasma Cell Myeloma
Author Information
Author(s): Olteanu Horatiu, Wang Huan-You, Chen Weina, McKenna Robert W, Karandikar Nitin J
Primary Institution: Department of Pathology, Medical College of Wisconsin
Hypothesis
This study examines the immunophenotypic differences of plasma cells in MGUS and PCM to predict disease progression.
Conclusion
MGUS cases with potential for disease progression lack CD19 expression on most plasma cells, similar to PCM plasma cells.
Supporting Evidence
- All MGUS patients had two subpopulations of plasma cells, one normal and one aberrant.
- Only 20 of 32 PCM cases showed an identifiable normal subpopulation at significantly lower frequency.
- MGUS patients with >90% CD19(-) plasma cells had a higher chance of disease progression.
Takeaway
Doctors looked at blood samples from patients with a condition called MGUS to see how it might change into a more serious disease. They found that if most of the blood cells don't show a certain marker, it could mean the disease might get worse.
Methodology
Bone marrow specimens from 32 MGUS and 32 PCM patients were analyzed using 4-color flow cytometry to assess plasma cell markers.
Limitations
The study had a limited follow-up period and a small number of cases analyzed.
Participant Demographics
MGUS cohort: 16 men and 16 women, mean age 59 years; PCM cohort: 21 men and 11 women, mean age 62 years.
Statistical Information
P-Value
p << 0.001
Statistical Significance
p << 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website